BluePath Solutions
Consulting firm founded in 2013 focused on health economics, outcomes research, modeling, data visualization, and value communications to support market access, pricing, reimbursement, and evidence generation for biopharmaceutical, medical device, and diagnostic clients. Headquarters in Los Angeles, CA.
Industries
Nr. of Employees
small (1-50)
BluePath Solutions
Products
Health Economics & Outcomes Research
Conducts research to design, generate, and disseminate evidence on clinical, economic, and humanistic outcomes to support healthcare decision-making.
Modeling & Data Visualization
Develops models and visual tools to analyze healthcare data and communicate product value to internal and external stakeholders.
Value Marketing & Communications
Transforms complex research data into clear brand messaging and value communication materials for healthcare stakeholders.
Health Economics & Outcomes Research
Conducts research to design, generate, and disseminate evidence on clinical, economic, and humanistic outcomes to support healthcare decision-making.
Modeling & Data Visualization
Develops models and visual tools to analyze healthcare data and communicate product value to internal and external stakeholders.
Value Marketing & Communications
Transforms complex research data into clear brand messaging and value communication materials for healthcare stakeholders.
Services
Design and execution of HEOR studies (literature reviews, epidemiology, surveys, EMR/chart reviews, statistical analyses) to generate evidence for payers and health systems.
Development of budget impact, cost‑effectiveness, and other decision analytic models with clean visualization and interactive tools for internal stakeholders and payer audiences.
Creation of value stories, training materials, slide decks, payer fact sheets, and multichannel content to translate evidence into actionable messaging.
Payer landscape analysis, coverage policy assessment, pricing strategy, and coding/reimbursement advice to support market entry and lifecycle access.
Preparation of annotations, reference binders, data‑on‑file documentation, AMCP Section 4 reports, and coordination of internal review processes.
Design and execution of HEOR studies (literature reviews, epidemiology, surveys, EMR/chart reviews, statistical analyses) to generate evidence for payers and health systems.
Development of budget impact, cost‑effectiveness, and other decision analytic models with clean visualization and interactive tools for internal stakeholders and payer audiences.
Creation of value stories, training materials, slide decks, payer fact sheets, and multichannel content to translate evidence into actionable messaging.
Payer landscape analysis, coverage policy assessment, pricing strategy, and coding/reimbursement advice to support market entry and lifecycle access.
Preparation of annotations, reference binders, data‑on‑file documentation, AMCP Section 4 reports, and coordination of internal review processes.
Expertise Areas
- Health economics and outcomes research (HEOR)
- Economic and decision analytic modeling
- Data visualization and interactive dashboards
- Value marketing and communications
Key Technologies
- Excel-based economic modeling
- VBA
- R / Shiny
- Python
News & Updates
Analysis of FDA removal of REMS programs for autologous CAR‑T therapies and implications for utilization and financial risk.
Survey and analysis on the shift from static HCEI formats to digital payer portals for delivering healthcare economic information.
Summary of CMS announcements regarding drugs selected for Medicare Part D price negotiations and implications for manufacturers.
Company founded in 2013.
Analysis of FDA removal of REMS programs for autologous CAR‑T therapies and implications for utilization and financial risk.
Survey and analysis on the shift from static HCEI formats to digital payer portals for delivering healthcare economic information.
Summary of CMS announcements regarding drugs selected for Medicare Part D price negotiations and implications for manufacturers.
Company founded in 2013.